Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Begelomab (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Sponsors ADIENNE
- 08 Jul 2017 This study has been completed in Spain.
- 21 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated